Member Info for matarakz

Good news more to comeMon 16:06
I am expecting a payout at some stage from the sale of Glycotest or ProAxsis.
This is where the shareholder value will come.
ProAxsis has proved its concept has a strong sales pipeline and will be profit making now. It is more appeal than most AIM companies.
Glycotest 10m funding values it at 20m before the royalties from fosun, it is carrying out 4 more trials in the US now and will launch HCC Q3.
PDSB has 3 stage 2 trials 1 under way and 2 very soon. Covid vaccine news on its way, buyout or merger possible.
All in NetScientific is funded for another year 3.5m cash in PF companies and 700k loan that it can draw on.
Mkt cap 4m cheap.
By baz9707

Qiagen is the market leader in pcr extraction market and was taken over by Thermofisher for $11.5 billion. If Novacyt can take 10% of the market, it would be transformational for Novacyt to become a big player in the industry.

Well done everyone here!

Let us always rememeber Pcr extraction products market Is bigger than Covid 19 tests market. Imho

This is the real deal! Imho

We are emulating Qiagen pathway - a leader in pcr extraction kits with over a bilion dollar revenue. It was taken over by Thermofisher this year for 11 .5 billion dollar. We are in the right company. Imho

Avacta is a biotech company without any phae 1 study. It was pumped because of covid19 diagnostic test, it would struggle to sell Covid products . No significant revenue, more dilutions. More than £200 million market cap is not justified. Imho Avacta’s fair value is 40-50p

Not Odx, being diagnostic company, Novacyt can easily launch Antibody test.

I am also invested in Sorrento , that was my question as well. Source of fund to pay off debt?
Maybe
1 Successfully raised fund?
2 JV/ investment from big Pharmas?
We would know the results this week. My target price is $25.imho

Good to top up. Imho

Novacyt Is in a different league. Launching Antibody is easier for Novacyt bacause it a diagnostic company. Odx and Genedrive - it Is a disadvantageous and
it won’t give benefit to the company.

https://www.investegate.co.uk/cadence-minerals-plc--kdnc-/rns/yangibana-works-construction-permit-granted/202006171058342480Q/

Another multibillion dollar project. Well done Cadence

Antigen test can be performed using Nose and throat swab and now saliva.

LOL! Good night

Have u fallen sleep during the Covid 19 Pandemic? We are talking about million figures in America Imho.

NEW – PathFlow™ Rapid Tests

The new PathFlow™ range of products will quickly expand to become your complete solution for the rapid diagnoses of Infectious Diseases…
My mind says Novacyt is launching Rapid Lateral flow test for Antibody and Antigen. This is the only missing link .
Microgen, part of Novacyt group is already selling different rapid Lateral flow tests. Hopefully my guess is right.

A sale of 1,000 units of Q16 and Q32 machines is possible this year imho.

@VanV, i respect your view on Avacta but it is very difficult to justify the market cap of more than £200 million. It was pumped because of covid 19 diagnostic products but it would be very difficult to penetrate the competitive international market.
Although , it has a promising technology but it still needs to be proven thru Phase 1 study to Phase 3 . At this moment , it has no phase 1 study yet. Imho, Avacta’s fair value is 40-50p IMHO. I’m only posting my view here in this board.

CaptainStanley
Avacta is overvalued with more than £200 million
It was pump because of covid 19 diagnostic test products
No significant revenue
No phase 1 trial
Imho, fair value 40-50p

My understanding is ‘ if there is no settlement between creditors and Dev+JV, the secured loan would become unsecured loan. Then it would be advantageous to Dev+co. During this time of crisis, goverment and courts are more sympathetic to the businesses. Imho